R&D
Partner Content
Donor Selection & Cell Source Summit
View the full event guide here As the allogeneic cell therapy space …
19804 items found
News
Seagen hails ‘practice-changing’ trial in bladder cancer
A combination of Astellas and Seagen’s Padcev with MSD’s Keytruda has …
R&D
Partner Content
6th Microbiome Movement – Animal Health & Nutrition Summit
This November, join your fellow microbiome experts from the livestock …
R&D
Partner Content
7th Microbiome Movement – Human Nutrition Summit
The 7th Microbiome Movement – Human Nutrition Summit will unite 100+ …
R&D
Partner Content
Gene Therapy Process Development Summit
Gene therapy developers are striving to platform their process …
News
Machine learning puts virtual drug screening into high gear
Researchers in Finland have combined virtual drug screening with …
News
AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer
Armed with the first phase 3 data for their TROP2-targeting …
News
Travere weaker after Filspari fails confirmatory trial
Shares in Travere Therapeutics have lost more than 40% of their value …
Market Access
Growing healthcare businesses with private equity
Healthcare companies perform a critical role in society globally. …
News
FDA panel votes against Intarcia’s GLP-1 implant
Intarcia Therapeutics’ take on the massively successful GLP-1 agonist …
Views & Analysis
How AI-powered adaptive design helped Eisai launch Leqembi
In July, when the FDA approved Eisai and Biogen’s Alzheimer’s drug …
News
Cancer Research UK earmarks £123m for Scottish R&D
Cancer Research UK (CRUK) has said it will award £123 million ($150 …
R&D
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...
Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Patients
Deep Dive: Patients & Partnerships 2024
IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Sales & Marketing
Sponsored
Seeking a single source of truth: Standardisation of the dat...
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
EHS&S for Biopharma & Pharma Summit
Implementing Corporate & Regulatory-Guided EHS Practices to Achieve Zero Biosafety, Ergonomic & Chemical Incidents for Employee Safety Across Global Facilities
R&D
Partner Content
Proteomic Based Drug Discovery Summit 2025
Determine Optimum Application of Proteomics to Accelerate Screening of Novel Targets, Unravel the Mode of Action, & Identify Biomarkers to Progress Small Molecule Drug Discovery & T
